ABL1 and breast carcinoma: Pharmacological selectivity is another consideration, as c-Abl is also commonly inhibited and this has been shown to promote cell proliferation in vitro.[27] Lack of patient selection may also have contributed, as Src activation is only present in around 40% of ER-positive breast cancers [7].